Subcutaneous · GLP-1 / FGF21 dual
HEC88473
4 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
4
Active
1
Recruiting
1
Completed
3
Sites
5
Countries
2
Endpoints
34
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
2
Phase 2
2
Trials by status
Recruiting
1
Completed
3
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
12
Other (unclassified)
9
Glycemic / diabetes
6
Weight & body composition
3
Cardiometabolic biomarkers
2
Patient-reported / QoL
2
Most-measured metrics
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
1
Body weight, absolute change (kg)Weight
1
Fasting glucose, changeGlycemic
1
Serious AEs (any)Safety/PK
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
4 of 4
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06148649Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus | Dulaglutide, HEC88473 Type 2 diabetes | HbA1c 7.5-10.5% | Ph 2 | Completed | 2 | Feb 2025 | — | |
| NCT07616037Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS | HEC88473 PCOS | Female | Ph 2 | Recruiting | 1 | Jun 2027 | — | |
| NCT04829123The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects | HEC88473 Healthy volunteers | BMI 18-40 | Ph 1 | Completed | 1 | Mar 2022 | — | |
| NCT05943886A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects | HEC88473 Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI ≤28 | Ph 1 | Completed | 1 | Feb 2023 | 2 |